Angela Freiden is taking up the role.
Angela Freiden has been appointed director of innovation & productivity at Helius Therapeutics, New Zealand’s largest licensed medicinal cannabis company.
The role involves coordinating an innovative pipeline of projects and products for Helius, driving continuous improvement and innovative inhouse processes, said CEO Carmen Doran.
"This will ensure that Helius delivers products in the most efficient way possible, shortening lead times and lessening costs."
To support Helius’ R&D programme, Freiden will develop and grow innovative collaborations across New Zealand and around the world. She will lead key funding applications to ensure the development and timely delivery of next-generation medicines.
In July, Helius became New Zealand’s first medicinal cannabis business to be awarded a GMP Licence to Manufacture Medicines and it plans to start exporting next year.
Freiden was previously General Manager and Non-Executive Director at New Beta and New Alpha Innovation in Hamilton, developing biopharmaceutical products for humans and animals.
She will work closely with Marten Vos, who was recently appointed Director of Research & Development.
